美吾華(芽堡生技) 牙齒幹細胞中國佈局

美吾華集團結盟四川禾邦  2011-06-14 旺報   由美吾華（1731-TW）、懷特（4108－TW）投資成立的芽堡生技布局大陸有成，該公司昨日宣布與四川禾邦集團簽署合作意向書，將共同推展大陸幹細胞儲存業務。該合作意向書是由芽堡生技董事長李成家與四川禾邦集團董事長劉文旭共同簽署。劉文旭表示，牙齒幹細胞（乳牙、智齒）比臍帶血、骨髓等更具有治療優勢與高反應療癒效果，該集團將以在地資源及與醫學中心及產學合作交流經驗，結合芽堡生技品質管制與保存庫管理經驗，共同攜手進軍大陸幹細胞儲存市場廣大商機。

台製面膜 陸客最愛!

陸客愛買排行榜 面膜狂刷30萬元!  東森新聞 2011-06-13 14:03  討論 (+)  調整字級：     話說人潮帶來錢潮，陸客到台灣，最愛買什麼？其實不是高價的精品或是紀念品，而是一盒不過百來元的面膜，業者告訴我們，說陸客特愛逛藥妝店，還指名買台製的面膜，因為不但比大陸買便宜，品質也比較有保障，甚至最高紀錄，還有豪客一口氣刷了30萬，買走200盒。大叔出手真豪氣，打包這滿滿一桌20幾盒面膜，就連店裡最大的袋子也裝不下，時髦的年輕陸客掃貨，更是指名要買台灣做的。大陸觀光客：「賣面膜啊，我沒試過想試一下，這挺好的，很保濕、很棒啊。」陸客來台就像當年台灣人到日本，愛逛藥妝店愛買保養品，因為台灣賣的不但價格比較便宜，品質也比大陸製的好，許多店家也早就針對陸客促銷，簡體字看板說這是「訪台最佳伴手禮」。以一家位於西門町的藥妝店為例，光是賣面膜給陸客，一天就能賣掉三、四百盒，自由行開放後，陸客年齡層下降，保養化妝品業績會再衝高，除此之外，始終名列陸客「愛賣排行榜」前茅的還有鳳梨酥。這家拿過台北市鳳梨酥比賽，冠軍的老店每天都是這盛況，客人實在太多，一次只能放10個人進門，其他人就得在騎樓排隊，即使不能刷卡，陸客捧著現金也要來搬。鳳梨酥業者：「差不多日賣三萬顆至四萬顆才夠，自由行的，單人的大概都消費有一、兩萬塊。」自由行後有名氣的老店更佔優勢，業者早已買下新店面準備擴充，估計業績可望成長三成。

If Augmentin banned in India, the harm will be greater than Taiwan

Glaxo's Augmentin banned in Taiwan. Will India follow? Tuesday, Jun 14, 2011, Agency: DNA  Augmentin, an antibiotic produced by GlaxoSmithKline (GSK), is set for a smooth sail in India notwithstanding the storm raging over it in Taiwan. Taiwan authorities on Saturday asked GSK to recall the drug — generic amoxicillin clavulanate — after tests by its health department detected the presence of di-isodecyl phthalate (DIDP), a chemical banned in that country. For the record, DIDP is used in the production of plastics. Somewhat predictably, a GSK spokesperson chose to play down the Taiwan episode, saying the level of DIDP identified in the samples tested was very low, much lower than what the US and EU authorities deem risky for humans. But local medical practitioners expressed concern at the presence of such substances in popular antibiotics. An internal medicine consultant from a hospital in Mumbai said it was all the more worrying because people tend to use antibiotics randomly and irrationally, thereby subjecting themselves to greater exposure to the plasticiser. Chandra M Gulhati, editor of Monthly Index of Medical Specialties, a reference journal for medical practitioners, said the authorities should take suo motu cognisance of issues related to quality or safety of medicines whenever they came up abroad. Still, nobody expects any action to be taken against Augmentin in India immediately. Augmentin is GSK's largest selling brand in India with annual sales of ¤240 crore, or around 10% of its revenues. Clearly, any action by the authorities could leave the company's financials dented, analysts said. Also, quality issues and recalls impact not just the revenues but also the brand image of a manufacturer, Nitin Bidikar, associate director, KPMG said. Drugs controller Surinder Singh and joint controller AB Ramteke could not be reached for comment. The GSK spokesperson said the company will work closely with Indian regulatory authorities and provide information and clarity as and when required. Gulhati drew attention to the technical issues involved in detection of such substances in the country, where laws mandate only the active ingredients to be printed on the label by the manufacturer and checked by the authorities. "In India, an examination would not have picked up the presence of the plasticiser," he said. This is because the plasticiser is not an active pharmaceutical ingredient but one of the pharmacologically inactive ingredients in the drug. "In Augmentin, amoxicillin and clavulanic acid are the active ingredients. All medicines contain inactive substances like colouring agents, binding agents and flavouring agents. The plasticiser was found in the flavouring agent in Taiwan."

Southern Taiwan Science Park posts double-digit sales growth

 2011/06/13 19:09:45 Taipei, June 13 (CNA) The Southern Taiwan Science Park had double-digit sales growth in March and April compared with the first two months of the year thanks to higher demand for flat panels and precision machinery, the park's administrator said Monday. Companies in the park had combined sales in March and April of NT$101.8 billion (US$3.52 billion) , up 20.36 percent from the January-February figure, the Southern Taiwan Science Park Administration said in a statement.The new figures brought the total sales of park companies to NT$186.3 billion for the first fourth months of the year. The Southern Taiwan Science Park is comprised of 110 companies based at the Tainan Science Park and another 64 companies based at the Kaohsiung Science Park, employing more than 60,000 people. Optoelectronics companies generated sales of NT$54.6 billion in the March-April period, 13.01 percent higher than the previous two-month period and the highest of the park's six major industries. The semiconductor industry came in second, with NT$38.7 billion in sales, up 25.67 percent from the previous period, followed by the precision machinery industry, which saw sales rise 62.9 percent from January and February to NT$6.3 billion. Biotechnology sector sales rose 54.7 percent to NT$919 million, communication industry sales were up 33.54 percent to NT$557 million, and computer industry sales rose 31.33 percent to NT$312 million.

Nangang biotech park gets conditional go-ahead

Publication Date：06/13/2011 Source： Taiwan Today  The Environmental Protection Administration provisionally approved a major development plan for a national biotech park on the site of a military arsenal in Taipei's Nangang District June 10. The development project, proposed by Taiwan's top research institute Academia Sinica, was at the heart of yearlong debate due to environmental concerns as the proposed site includes wetlands and is susceptible to flooding. The newly passed plan saw the floor area for buildings scaled down to 3.05 hectares, about one-third of the originally proposed area, and another 11.94 hectares of surrounding land reserved for wetlands and ecological research. The park, adjacent to Academia Sinica, will cover a total area of 25.31 hectares. "The biotech park project will boost the development of Taiwan's clean industry in the long term," Academia Sinica President Wong Chih-huey said. He added that with the area to be built on reduced to a minimum, the plan will meet the need for ecological conservation and habitat diversity. "There is no conflict between the biotech industry and environmental protection," Wong said. According to the development plan, the biotech park will house a biotechnology development center, bioinformatics center, national laboratory animal center and other research and support facilities. Permission to proceed with the project came with conditions, with the environmental assessment review panel requiring the developer to propose sewage and drainage management standards for the biotechnology industry before the park becomes operational. Academia Sinica must also secure silver-rating green building certification in five categories, and the ecological conservation area and wetland restoration projects must qualify as environmental education sites. The institute is also required to ensure that the flood-retention functions of the area remain intact. The whole project is scheduled for completion in June 2016, according to Academia Sinica, with a budget of NT$22.5 billion (US$781 million). The park is expected to create 2,000 research and development jobs. (THN)